Orrick Advises ANI Pharmaceuticals on Acquisition of Amerigen Generic Product Portfolio


Orrick has advised ANI Pharmaceuticals on its acquisition of a U.S. portfolio of 23 generic products from Amerigen Pharmaceuticals for $52.5 million in cash and up to $25 million in contingent profit share payments over the next four years. The portfolio includes 10 commercial products, three approved products with launches pending, four filed products and four in-development products, as well as a license to commercialize two approved products.  

The Orrick team advising ANI was led by David Schwartz and included David Gold, Jamie Kamen, Elena Kamenir, Amy Ray, James Larkin, John Narducci and Diana Gillis.